Latest News
US close: Stocks close higher as rate cuts remain in focus
Wall Street stocks closed higher on Monday, with attention remaining focused on the Federal Reserve as hopes of a 50 basis point cut to interest rates began to fade.
London close: Stocks finish positive as Brexit fears see sterling slip further
London stocks finished just above the waterline by the close on Monday, as the pound was dented by political woes.
Next PM must 'act fast' to get UK economy on track, says CBI
The Confederation of British Industry has urged the next Prime Minister to "act fast" to get the stalled economy back on the path of growth in a business manifesto released on Monday.
Equifax to pay $600m settlement over data breach
Credit reporting giant Equifax has been fined $600m by New York Attorney General Letitia James on Monday, in what is the largest ever settlement over a data breach.
Midwich trading in line as acquisitions develop
Midwich Group reported that its revenues and margins grew in the first half of the year after recent acquisitions made strong contributions on Monday, though its full-year expectations remained unchanged.
Broker tips: Asos, Tui
Analysts at JP Morgan Cazenove downgraded shares of fashion retailer Asos to 'neutral' from 'overweight' on Monday following the group's profit warning last week.
Europe close: Markets finish higher as Gulf crisis boosts oil plays
European markets finished in positive territory on Monday, as the Gulf crisis provided a boost for oil producers although investors were still keeping a wary eye on the European Central Bank meeting later in the week.
Director dealings: Globalworth founder ups stake
Globalworth Real Estate Investments revealed on Monday that chief executive Ioannis Papalekas had acquired 3m ordinary shares in the AIM-listed group.
FTSE 250 movers: Ted Baker rallies; PPHE Hotel Group dips
London’s FTSE 250 was up 0. 21% at 19,662. 51 in afternoon trade on Monday, with Ted Baker pacing the gains.
Fitch downgrades Boeing outlook to 'negative' on 737 MAX concerns
Fitch downgraded its outlook on Boeing to 'negative' from 'stable' on Monday, citing regulatory uncertainty over when the plane maker's best-selling 737 MAX jets will return to service.
CBI accuses Ofgem of not prioritising climate emergency
UK energy regulator Ofgem was on Monday accused by a leading business lobby group of failing include climate change when considering policy goals.
Banks abandoning England's poorest areas
Banks have been closing branches in the poorest communities in England four times faster than in wealthy areas, according to research from Pockit.
US open: Mixed start to trading ahead of earnings deluge
Wall Street trading got off to a mixed start on Monday, with attention remaining focused on the Federal Reserve as hopes of a 50 basis point cut to interest rates began to fade.
FTSE 100 movers: Tui travels higher on Stifel note; Whitbread under pressure
London's FTSE 100 was up 0. 1% at 7,512. 52 in afternoon trade on Monday.
Learning Technologies revenues, underlying earnings soar in 'strong' first half
Digital learning and talent management firm Learning Technologies saw strong sales momentum in the first half of its trading year, with underlying earnings "materially ahead" of expectations.
Homebase acquires Bathstore but 91 locations set to close
Homebase on Monday confirmed the acquisition of Bathstore, taking control of 44 stores and the collapsed bathroom retailer's website.
BT to move HQ to new Aldgate site
BT said on Monday that it will relocate its headquarters from St Paul's to a new site in Aldgate, with the move expected to be completed by the end of 2021.
UK's Alan Duncan quits as Foreign Office minister
UK Foreign Office minister Alan Duncan resigned on Monday before the probable installation of Boris Johnson as prime minister, joining other senior government members who said they would not serve under the leadership favourite.
Tiziana Life Sciences pleased with latest results from Milciclib trial
Biotechnology company Tiziana Life Sciences announced preliminary topline clinical data from a Phase 2a trial of Milciclib as a monotherapy in patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, on Monday.